Skip to main content
Clinical Trials/NCT07174245
NCT07174245RecruitingNot Applicable

Pregnancy and Postpartum Continuous Glucose Monitoring in Gestational Diabetes

Icahn School of Medicine at Mount Sinai1 site in 1 country40 target enrollmentStarted: August 5, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
40
Locations
1
Primary Endpoint
Sensitivity of postpartum TIR <96%

Study Overview

Brief Summary

Gestational diabetes (GDM) is one of the most common complications of pregnancy, and up to one third of women with GDM will have abnormal blood sugars after their pregnancy. To screen for abnormal blood sugars, standard of care is a 4-12 week postpartum oral glucose tolerance test (OGTT). However only 17-60% of women actually have this test performed. This study is to assess continuous glucose monitor data from the third trimester and up to 14 days postpartum to find predictors of postpartum OGTT results.

Detailed Description

Those with GDM in current pregnancy using a Dexcom Continuous Glucose Monitoring (CGM) are eligible for enrollment. Participants use their CGM as usual during pregnancy and wear one sensor postpartum. They have their standard of care OGTT performed at around 6 weeks. They then complete a remote questionnaire after OGTT.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of gestational diabetes during current pregnancy
  • •age 18 or older
  • •prescribed Dexcom G7

Exclusion Criteria

  • •Pregestational diabetes
  • •known skin adhesive allergy which inhibits ongoing use of CGM
  • •chronic oral steroid use.

Arms & Interventions

Participants with Gestational diabetes GDM

All participants who wear CGM and have their postpartum OGTT

Intervention: continuous glucose monitor (Device)

Outcomes

Primary Outcomes

Sensitivity of postpartum TIR <96%

Time Frame: up to 12 weeks postpartum

Sensitivity of postpartum time in range (TIR) \<96% to predict dysglycemia on OGTT. Range 70-180 mg/dL. Sensitivity determined by true positives of TIR \<96% and abnormal OGTT and false negatives would be TIR \<96% with normal OGTT.

Sensitivity of postpartum TIR <96%

Time Frame: up to 12 weeks postpartum

Sensitivity of postpartum time in range (TIR) \<96% to predict dysglycemia on OGTT. Range 70-180 mg/dL. Sensitivity determined by true positives of TIR \<96% and abnormal OGTT and false negatives would be TIR \<96% with normal OGTT.

Secondary Outcomes

  • Specificity of postpartum TIR <96%(up to 12 weeks postpartum)
  • Experience survey questionnaire(up to 12 weeks postpartum)
  • Specificity of postpartum TIR <96%(up to 12 weeks postpartum)
  • Experience survey questionnaire(up to 12 weeks postpartum)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Grenye O'Malley

Associate Professor

Icahn School of Medicine at Mount Sinai

Study Sites (1)

Loading locations...

Similar Trials